Taking on board potential Zantac litigation headwinds
16/08/22 -"To factor in the negative investor sentiment regarding the potential adverse implications of the Zantac trial in the US (expected to start by end-Aug 2022), we have injected a discount of 30% into ..."
Pages
71
Language
English
Published on
16/08/22
You may also be interested by these reports :
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...